Back

StatPearls, LLC

  • Cannabidiol
  • Drug Resistant Epilepsy
  • Epilepsies, Myoclonic
  • Lennox Gastaut Syndrome
  • Tuberous Sclerosis

Cannabidiol (CBD) in Clinical Care

This activity focuses on cannabidiol’s (CBD) role in managing refractory epilepsy. Participants will explore indications, actions, and contraindications pertinent to CBD’s efficacy in managing Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. This discussion also thoroughly reviews CBD’s mechanism of action, adverse event profile, and ongoing research trials involving this drug. Additionally, understanding CBD’s pharmacology helps healthcare professionals to tailor treatment plans to individual patient needs. Enhancing patient care and optimizing outcomes in epilepsy, neuropathic pain, and anxiety disorders requires emphasis on the critical role of the interprofessional healthcare team in overseeing CBD therapy.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AAPA Category 1 Credit™Up to 2 creditsAMA PRA Category 1 Credit™Up to 2 creditsNursingUp to 2 creditsPharmacyUp to 2 credits

MOC types

ABS — Accredited CMEUp to 2 pointsABPATH — Lifelong LearningUp to 2 pointsABA — Lifelong LearningUp to 2 pointsABTS — Accredited CMEUp to 2 pointsABIM — Medical KnowledgeUp to 2 pointsABS — Self-AssessmentUp to 2 pointsABP — Lifelong Learning and Self-AssessmentUp to 2 pointsABTS — Self-AssessmentUp to 2 points

FDA REMS

No

Qualifies for MIPS

No

Target Specialties

Cross-Specialty

Relevant across 8 specialties.

Pricing

Fee varies

This provider typically $49–98

See fees on statpearls.com

Listed by the provider

  • Article / monograph / reference
  • Credit · Up to 2 credits
  • MOC · Up to 2 points
  • Fee varies · this provider typically $49–98
  • Released
    Sep 1, 2026
  • Last day to claim credit
    Sep 1, 2029 3 years left